DA Davidson Downgrades Medifast to Underperform, Lowers Price Target to $17.5
Portfolio Pulse from Benzinga Newsdesk
DA Davidson has downgraded Medifast (NYSE:MED) from Neutral to Underperform and lowered the price target from $25 to $17.5.
June 05, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
DA Davidson downgraded Medifast from Neutral to Underperform and reduced the price target from $25 to $17.5, indicating a negative outlook.
The downgrade from Neutral to Underperform and the significant reduction in the price target from $25 to $17.5 suggest a negative outlook for Medifast. This is likely to result in a short-term decline in the stock price as investors react to the analyst's revised expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100